PERCEPTIVE ADVISORS LLC
Q1 2024 13F-HR/A Holdings
Net value change ($000)
+1,235,508
(27.6%)
New positions
25
Sold out positions
17
Turnover %
15.7%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| IOVA | 188,233 | 193.3% |
| Fusion Pharmaceuticals Inc. | 119,076 | 450.3% |
| APGE | 85,841 | 168.1% |
| VKTX | 81,516 | NEW |
| MDGL | 79,842 | 228.3% |
| NBIX | 75,264 | 210.9% |
| SLDB | 70,532 | 328.6% |
| Intra-Cellular Therapies, Inc. | 65,296 | 844.2% |
| PCVX | 63,670 | 93.1% |
| Astria Therapeutics, Inc. | 60,499 | 196.7% |
Top Reduces (Value $000, Stocks/ETFs)
| LIANY | -257,256 | -100.0% |
| CymaBay Therapeutics, Inc. | -95,056 | -100.0% |
| FOLD | -67,618 | -17.0% |
| RayzeBio, Inc. | -46,258 | -100.0% |
| RAPT | -42,191 | -79.3% |
| BBIO | -26,944 | -38.2% |
| AMLX | -26,662 | -96.9% |
| ABBV | -17,489 | -47.4% |
| ASND | -16,648 | -100.0% |
| VRNA | -16,336 | -21.3% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
41,093
(0.7% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|